Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

659
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
659
COP Coated Vesicles00:59

COP Coated Vesicles

9.7K
Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...
9.7K
Pinching-off of Coated Vesicles01:32

Pinching-off of Coated Vesicles

3.3K
Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...
3.3K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

772
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
772
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy.

Medicina (Kaunas, Lithuania)·2026
Same author

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Current oncology (Toronto, Ont.)·2026
Same author

Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Role of liquid biopsy in genitourinary (GU) cancers.

Expert review of molecular diagnostics·2026
Same author

Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists.

The Prostate·2026
Same author

Less Can Be Enough: Optimizing Abiraterone Acetate Dosing With Food to Improve Access and Maintain Efficacy in Metastatic Castration-Resistant Prostate Cancer.

JCO global oncology·2026

Related Experiment Video

Updated: Sep 23, 2025

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
07:29

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis

Published on: November 12, 2015

20.0K

Vortex keratopathy associated with ribociclib.

Alper Türkel1, Sibel Özdoğan2, Emre Yekedüz1

  • 1Division of Medical Oncology, 146995Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|May 16, 2022
PubMed
Summary
This summary is machine-generated.

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, like ribociclib, can cause rare eye side effects such as vortex keratopathy in breast cancer patients. Early detection through regular eye exams is crucial for effective management of these visual disturbances.

Keywords:
Ribociclibbreast cancercombination treatmentcyclin-dependent kinases 4 and 6vortex keratopathy

More Related Videos

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.0K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.4K

Related Experiment Videos

Last Updated: Sep 23, 2025

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
07:29

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis

Published on: November 12, 2015

20.0K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.0K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.4K

Area of Science:

  • Ophthalmology
  • Oncology
  • Pharmacology

Background:

  • Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors represent a new class of drugs for hormone receptor-positive (HR) and human epidermal growth factor receptor 2 (HER-2)-negative breast cancer.
  • These inhibitors offer improved progression-free survival over standard therapies, but common side effects include neutropenia, nausea, leukopenia, fatigue, and diarrhea.
  • Vortex keratopathy is identified as a rare ocular side effect in patients undergoing treatment with CDK4/6 inhibitors, specifically ribociclib.

Observation:

  • A 68-year-old female with advanced HR+/HER2- breast cancer developed blurred vision after initiating ribociclib and fulvestrant treatment.
  • Ophthalmic examination revealed bilateral vortex keratopathy, characterized by subepithelial haze and whorl-like opacities, more pronounced in the left eye.

Findings:

  • Ribociclib treatment was discontinued upon observation of vortex keratopathy.
  • No changes in corneal appearance or visual acuity were noted during the subsequent one-month follow-up period.

Implications:

  • This case highlights vortex keratopathy as a rare but potential ocular side effect of ribociclib in breast cancer patients.
  • Regular ophthalmological monitoring is recommended for patients undergoing CDK4/6 inhibitor therapy to facilitate early detection and management of adverse events.